patent.fyi
Applications  /  US 2026/0356810
United States Patent Application Publication

US 2026/0356810 A1

Published
Nov 12, 2026
Filed
Oct 13, 2023
Earliest date on the face
Oct 14, 2022
Classification
C07D 295/192
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

No entries.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference material for analytical training

A piperazine sulfonamide and a structurally related reference compound serve as analytes in a laboratory chromatography exercise. Separate stock solutions supply single-analyte vials and a mixed vial, and the sample solvent supplies a blank. Analysts inject the blank, the individual solutions, and the mixture into a reversed-phase liquid chromatograph and use the individual retention times to assign peaks in the mixture.

Component substitution

Hydrochloride salt for aqueous stock preparation

For a piperazine sulfonamide with a protonatable nitrogen, a hydrochloride salt replaces the free base in an aqueous stock. The weighed salt dissolves in purified water, and its formula mass and measured assay value determine the concentration of the parent compound. The stock is diluted into the assay medium, and the final pH and solution clarity are recorded.

Parameter or scale variation

Eight point neuronal concentration series

Cultured neurons occupy a 96-well plate, with three wells per concentration and separate vehicle and unstressed controls. A threefold dilution series supplies eight final concentrations from 0.0137 to 30 micromolar at a constant vehicle fraction. The cells receive the compound for 24 hours before a defined oxidative challenge, and a viability readout measures survival 24 hours after the challenge.

Microscale screen for crystalline solid forms

A vial array holds 5 milligrams of a piperazine sulfonamide per vial and 0.25 milliliters of solvent or solvent mixture, with duplicate vials for each condition. The vials equilibrate at 40 °C for one hour and cool to 20 °C over two hours. Recovered solids undergo powder X-ray diffraction and thermogravimetric analysis to compare crystal forms and measure mass loss associated with retained solvent.

Combination with existing systems

Compound perfusion in a barrier chip

A two-channel microfluidic chip places brain endothelial cells in the perfused channel and neurons in the adjacent channel, with a porous membrane between them. A pump introduces the dissolved piperazine sulfonamide into the endothelial channel while the neuronal channel receives compound-free medium at its inlet. Liquid chromatography with mass spectrometry measures compound concentration in both outlets, and microscopy measures neuronal survival after a defined stress.

Automated or data-driven variant

Automated imaging of neurite regrowth

A multiwell plate contains neurons with established neurites, and a motorized microscope records baseline images at fixed coordinates. A controlled injury precedes robotic dispensing of the piperazine sulfonamide and vehicle, and the microscope revisits the same fields at 6, 24, and 48 hours after dosing. Image analysis measures total neurite length per surviving neuron, and software compares each well with its post-injury baseline and contemporaneous vehicle controls.

Cite aspatent.fyi, US 2026/0356810 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356810/, SHA-256 ade1a3c17d007044691701092b20b98c50c33db3cd5f51c8136456fa48e41bfa
First published
Permanent addresshttps://patent.fyi/US20260356810/
Content fingerprint (SHA-256)ade1a3c17d007044691701092b20b98c50c33db3cd5f51c8136456fa48e41bfa
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi